Introduction: Data from different healthcare systems on relative cost-effectiveness of
during one outcome year and a composite measure of risk-domain asthma control (no asthma-related hospital attendance, acute oral corticosteroids, or consultation for lower respiratory tract infection).
Results: Patients prescribed ICS dose step-up (n = 3036) had significantly lower baseline-adjusted, mean asthma-related healthcare costs during the outcome year than those prescribed FDC ICS/LABA (n = 3036; mean difference, £124/year). ICS dose step-up had 56% probability of being less costly and marginally less effective (a trade-off), with ICER of £51,449 per additional patient controlled with FDC; and ICS dose step-up had 44%
probability of being the preferred treatment strategy (less costly and more effective). In a second comparison, ICS step-up (n = 3232) had 100% probability of being cheaper and more effective than adding LABA to ICS via separate inhalers (n = 6464). Conclusion: For asthma step-up therapy, increasing ICS dose using extrafine-particle ICS is significantly less costly from the payer perspective and marginally (non-significantly) less effective than FDC ICS/LABA therapy containing standard fine-particle ICS. These findings apply primarily to the UK healthcare system but warrant consideration when developing guidelines in settings with strong economic constraints. health-related quality of life impairment [3] . The treatment of asthma is expensive, costing the UK National Health Service (NHS) an estimated £1 billion per year in direct costs, mostly attributable to the cost of prescription medications and hospital admissions [2, 4] . Healthcare resource use and the direct costs of asthma are highest for patients with suboptimal asthma control [5] [6] [7] . Considering these costs, it is of utmost importance to generate real-life cost-effectiveness data to help decision-makers and clinicians in their decisions regarding the choice between available treatment options.
The goal of asthma therapy is to achieve the two facets of asthma control, namely, current symptomatic control and minimized risk of future acute exacerbations, which can be life threatening [3] . Asthma therapy is prescribed using a stepwise approach, beginning with [3, 8] .
These recommendations are based on the results of randomized controlled trials (RCTs) [3, 8] ; however, RCT results have limited generalizability to actual clinical practice. By one estimate up to 95% of patients with asthma would not be eligible for RCTs because of restrictive RCT eligibility criteria, such as the exclusion of smokers or obese patients [9] . Moreover, adherence to therapy and inhaler device technique are better in RCTs than among patients in clinical practice [10, 11] . Relevantly for the step-up comparisons between increasing ICS dose and add-on LABA, most RCTs require enrolled patients to demonstrate substantial reversibility of airflow obstruction to a SABA, thereby selecting for bronchodilator responsiveness and excluding the estimated 70% of patients with asthma who fail to demonstrate sufficient bronchodilator reversibility at any given point in time [9] .
Cost-effectiveness analyses of asthma therapies are usually based on economic models drawing on data from RCTs of 12-16 weeks' duration [12] [13] [14] [15] . However, long-term clinical practice data may be more directly relevant to inform economic decisions regarding treatment choices for asthma, and effectiveness parameters such as annual exacerbation rates may be more appropriate for making treatment decisions [16, 17] . In addition, most economic models relied on RCTs in which standard fine-particle ICS were administered, namely, ICS with particles of median mass aerodynamic diameter (MMAD) of[2-5 lm.
Instead, the newer extrafine-particle ICS (MMAD, *1 lm) may better treat the small airways, where inflammation is often present in asthma, and thus may be more effective than fine-particle ICS, at least for patients with small airway involvement [18, 19] .
In a prior historical matched cohort study comparing step-up alternatives for patients with asthma treated in community settings [20] , we found that increasing the ICS dose was as effective in controlling exacerbations over the subsequent year as adding a LABA by fixed-dose combination (FDC) ICS/LABA inhaler. The objective of the present historical matched cohort cost-effectiveness analysis was to compare direct asthma-related healthcare costs and cost-effectiveness from the UK NHS perspective of three common step-up options for asthma: increased dose of extrafine-particle ICS, add-on LABA by FDC ICS/LABA inhaler, and add-on LABA by separate inhaler. Our hypothesis was that increasing the dose of an extrafine-particle ICS would be a cost-effective alternative to therapy with ICS plus LABA in combination or separate inhalers for adults with evidence of persistent asthma. Additionally, we hypothesized that FDC ICS/LABA inhalers would be more cost-effective than separate ICS/LABA inhalers.
METHODS

Data Sources and Patients
The anonymized patient data for this matched cohort study were drawn from two UK primary obtain for this non-interventional study using anonymized data. The study was conducted according to standards recommended for observational research (further details in the supplementary material) [25] .
The study period ran from January 1997 through January 2011. We included patients with asthma and no other chronic respiratory disease who were 12-80 years old. We excluded active smokers who were 61-80 years old because undiagnosed or comorbid chronic obstructive pulmonary disease is more likely in this older age group than in younger patients [3, 8] . Additional inclusion criteria were ICS monotherapy for asthma during one baseline year; a step up in asthma therapy as one of the three options described below; and 2 years of continuous records in the GPRD or the OPCRD, including one baseline year before and one outcome year after the step-up date (defined as the index date).
The three step-up options were as follows: (1 attendance, out-of-hours attendance, or outpatient hospital attendance; and (2) no prescription for an acute course of oral corticosteroids [32] ; and (3) no primary care consultation for lower respiratory tract infection [33, 34] .
Statistical Analyses
We conducted matched cohort analyses, using two-way matching for the three cohorts, to compare outcomes for age-and sex-matched (Table S2 in  the  supplementary  material) . Two-way comparisons of summary costs between matched cohorts were carried out using conditional logistic regression. Generalized linear models with a log link and gamma distribution were used to estimate adjusted mean asthma-related healthcare costs per year during the outcome period. Differences in adjusted mean costs are reported with 95% confidence intervals (CIs) found by bootstrapping methods, using 1000 random samples taken, with replacement, from the dataset [35] .
The effectiveness of treatments for matched cohorts was compared via the difference in the proportion of patients with asthma control during the outcome year, both unadjusted and adjusted for potential confounders. Adjusted proportions were estimated using generalized linear models with a logit link and binomial distribution. Proportions and differences in proportions of patients with asthma control were reported with 95% CIs found by bootstrapping methods, using the 1000 random samples taken, with replacement, from the dataset. The two-way differences in total asthma-related costs and proportions of patients with asthma control for the 1000 random samples were displayed graphically on cost-effectiveness planes. When the point estimates for differences in costs and effectiveness indicated a trade-off between treatments ( Fig. 1 , quadrants I and III), we calculated an incremental cost-effectiveness ratio (ICER) as the ratio of the difference in total asthma-related healthcare costs per patient per year (namely, the incremental cost) to the difference in proportions of patients with asthma control (namely, the incremental gain in effectiveness). When all the replicated data were in one quadrant of the cost-effectiveness plane, the ICER was reported with a 95% CI found by bootstrapping methods. When replicated data covered more than one quadrant, we produced a cost-effectiveness acceptability curve (CEAC) in conjunction with the ICER [36] [37] [38] .
RESULTS
Patients
We identified 5492, 9207, and 20,657 eligible patients who were prescribed extrafine-particle ICS dose step-up, add-on LABA by FDC ICS/ LABA inhaler, and add-on LABA to ICS by separate LABA inhaler, respectively. The Table S3 in the supplementary material. Approximately 22% of patients in comparisons 1 and 2 were smokers, and approximately 18% were ex-smokers (Table S3) . In all matched cohorts uncontrolled asthma was associated with increased costs (Table S7) . The percentage of patients meeting the risk-domain asthma control measure increased from 65% at baseline to 75% in both cohorts during the outcome year. The complete effectiveness results for comparison 1 have been previously published [20] .
During the outcome year, asthma-related resource use was similar in the two cohorts with the exception of expected differences related to study design, such as use of ICS and FDC ICS/LABA inhalers and a greater number of SABA inhalers used by the ICS step-up cohort ( Table 1) .
The mean baseline-adjusted, asthma-related healthcare costs for patients in the ICS step-up cohort were significantly lower than those for patients in the FDC ICS/LABA cohort (mean, £203 vs. £327; Table 2 ). When adjusted mean costs were combined with the adjusted effectiveness results-using asthma control as the effectiveness measure-there was a 56% probability that stepping up to a higher dose of extrafine-particle ICS would be less costly but less effective (a trade-off) and a 44% probability that ICS step-up would be the preferred treatment strategy (less costly and more effective). The uncertainty around the point estimates is illustrated in the cost-effectiveness plane (Fig. 1a) . The point estimate for the ICER was £51,449. The CEAC showed that for no additional cost (willingness to pay = £0) an increased dose of the extrafine-particle ICS was the cost-effective option, since a zero value for the willingness to pay implies that only the cost is important in the cost-effectiveness calculation (Fig. 2) . (Table S3 in the supplementary material).
The percentage of patients meeting the risk-domain asthma control measure increased from 65% at baseline to 75% in the ICS step-up cohort and to 71% in the separate ICS ? LABA cohort at outcome.
During the outcome year, most categories of asthma-related resource use and costs were significantly lower for the ICS step-up cohort (Table 3) , and the mean baseline-adjusted, asthma-related healthcare costs for patients in the ICS step-up cohort were significantly lower compared with those for patients remaining on the same ICS dose but adding a separate LABA (£204 vs. £337; Table 2 ). When costs were combined with the adjusted effectiveness results, there was a 100% probability that stepping up to a higher dose of extrafine-particle ICS would be less costly and more effective than adding a LABA by separate inhaler (Fig. 1b) .
DISCUSSION
In this matched cohort cost-effectiveness study, UK patients stepping up to a higher dose of extrafine-particle ICS had significantly lower baseline-adjusted mean asthma-related healthcare costs compared with patients stepping up to an FDC ICS/LABA inhaler (mean difference of £124 per annum) during one outcome year. When these costs were combined with the adjusted effectiveness results, there was a 56% probability that Confidence intervals determined using bootstrapping methods with 1000 random samples CI confidence interval, FDC fixed-dose combination, ICER incremental cost-effectiveness ratio, ICS Inhaled corticosteroid, LABA long-acting b 2 -agonist, OR Odds ratio a Adjusted for: smoking status (current smoker/ex-smoker/nonsmoker/not specified), outpatient department attendance for asthma/lower respiratory reasons, number of acute oral corticosteroid prescriptions, and oral thrush b Confidence intervals determined using bootstrapping methods with 1000 random samples c Adjusted for baseline asthma-related healthcare costs d Adjusted for number of acute oral corticosteroid prescriptions stepping up to a higher dose ICS would be less costly but less effective (a trade-off); a point estimate for the ICER, the monetary value of the intangible benefit to patients or society beyond the cost to achieve an additional controlled patient using an FDC ICS/LABA inhaler, was £51,449, reflecting the significantly higher costs of FDC therapy and the non-significant difference in effectiveness between treatments.
There was a 44% probability that stepping up to a higher dose of extrafine-particle ICS would be the preferred treatment strategy (less costly and more effective). In our second comparison, ICS step-up was the preferred treatment strategy compared with adding LABA via separate inhaler: there was a 100% probability that stepping up to a higher dose of extrafine-particle ICS would be less costly and more effective. Of the two add-on LABA alternatives (comparison 3, reported in the supplementary material) prescribing an FDC ICS/LABA inhaler was more costly but also more effective (with 100% probability) than prescribing a separate add-on LABA inhaler. This study compared asthma-related direct costs for different step-up strategies in a primary care setting, which is where most patients with asthma receive treatment in the UK, as in many countries [39, 40] . There are only a few studies that have examined real-life comparative costs for asthma step-up therapy [41, 42] . For patients with recent exacerbation or frequent SABA use identified in a recent retrospective cohort study conducted using a large US health insurance dataset, Hagiwara and coworkers [41] found that fluticasone/salmeterol combination was more effective in decreasing exacerbations and SABA use but more expensive than ICS dose step-up with fluticasone. In a broad United States (US) asthma population studied in was not reported) [42] . Other published cost-effectiveness analyses based on short-term RCT results report that FDC ICS/LABA therapy, while more expensive, usually meets benchmarks for cost-effectiveness [12] [13] [14] [15] .
Administering LABA by separate inhaler was not a cost-effective alternative in this study as compared with either ICS step-up or an FDC ICS/LABA inhaler. Similar findings were reported in prior RCTs [13] . In addition, administering LABA by separate inhaler is discouraged by asthma guidelines because LABA monotherapy (without ICS) has been associated with serious adverse asthma-related outcomes, including deaths, seen in early trials [8, 43] . Instead, an FDC ICS/LABA inhaler is recommended to ensure that patients take concomitant ICS.
A strength of this study is the large patient population, with over 38,000 patients studied, and the minimal exclusion criteria designed to capture data for a broad general population treated for asthma in primary care. Treatment cohorts were matched according to several criteria reflecting baseline asthma severity and control. Effectiveness measures were adjusted for residual confounding. Nonetheless, we cannot exclude the possibility of unrecognized confounders, including measures that were not available for all patients, such as smoking status and socioeconomic status, or that were not present in the database, such as pack-years of smoking. We were limited to the available database information in developing our asthma control measure; however, it would have been of interest to also include patient-reported outcomes (including actual SABA use rather than inhalers prescribed) in our definition of asthma control, as 58-65% of each cohort were evaluated as controlled at baseline according to our measure. Nevertheless, all patients were prescribed a step-up in therapy at the index date, which suggests that they or their physician did not consider their asthma to be well-controlled.
We had no way to measure patient satisfaction with therapy; however, we inferred from the treatment change data in the companion effectiveness study that there were no major differences in patient satisfaction between ICS step-up and FDC ICS/LABA step-up as the same proportions of patients in the two cohorts changed therapy during the outcome year [20] . Nevertheless, the issue of patient satisfaction with step-up therapy would be an important outcome to explore in a pragmatic trial. Patient satisfaction and patient preferences are potentially important influences on patient adherence to therapy and hence must be factored into clinical prescribing decisions [3, 8] . In addition, ICS doses should be tailored to the level of symptom control, lung function, and exacerbations, all relating to the degree of airways inflammation. Double counting may have occurred in this analysis because the numerator included the difference in costs of asthma-related resource utilization and the asthma control effectiveness measure was a function of asthma-related events. Therefore, the cost estimates in the ICERs are interpreted as the willingness-to-pay over and above the cost to achieve an additional controlled patient. In other words, ICERs in this case represent the monetary value of the intangible benefit to patients or society beyond the cost to achieve an additional controlled patient over the outcome period [44] . In addition, our study findings apply primarily to the UK healthcare system, and further investigations are needed from other perspectives, using different effectiveness measures, and in the setting of other healthcare systems, as costs are highly variable among countries. Moreover, prescribing preferences can vary according to location.
Assessment of indirect costs is needed as well.
We chose to investigate extrafine-particle beclomethasone, with aerosol particle MMAD of 1.1 lm, for the ICS step-up therapy because of its good distribution to the small airways, often a site of persistent inflammation in patients with poorly controlled asthma [18, [46] [47] [48] . In a prior, similarly designed cost-effectiveness study of patients initiating ICS therapy for asthma, we found that initiating with an extrafine ICS as compared with standard fine-particle ICS (MMAD of 2.4-3.2 lm, depending on formulation) had C84%
probability of being the preferred treatment, i.e., less costly and more effective, in both the UK and the USA [49] . 
CONCLUSIONS
We found that, among available step-up therapy alternatives for adults with persistent asthma on ICS monotherapy cared for in UK clinical practice, adding a LABA via separate inhaler is the least cost-effective option.
Increasing extrafine-particle ICS dose is significantly less costly from the payer perspective and marginally (non-significantly) less effective than FDC ICS/LABA therapy containing standard fine-particle ICS. From the UK NHS payer perspective, the cost to achieve an additional controlled patient using an FDC ICS/LABA combination rather than ICS dose step-up using extrafine particles is very high (£51,449). In countries with strong economic constraints, this may lead to questioning the recommendation of FDC ICS/LABA as first choice when treatment step-up is required, especially when considering that extrafine-particle ICS dose step-up has a 44% probability of being the cost-effective option relative to FDC ICS/LABA. These findings warrant further investigation in other healthcare systems and with a range of ICS in pragmatic trials and observational studies. McQueen were employees of RiRL, which conducted this study and which has conducted paid research in respiratory disease on behalf of the following other organizations in the past
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